Healthcare AI Startup Funding 2025-2026

What are all the funding deals in the healthcare AI market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play healthcare AI companies between August 2025 and July 2026. We define the healthcare AI market as AI software and models used by providers, payers, life sciences companies, medtech firms, and public health bodies to improve clinical care, operations, and research.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source.

How active has fundraising been in the healthcare AI market?

As of July 2026, fundraising in the healthcare AI market has been active and broad across the past 12 months. Companies raised 63 disclosed equity rounds and $3.16B combined, which works out to 5.73 deals per month.

The deal count shows that healthcare AI is not a narrow one-company story. The dataset includes 61 unique companies, so the market has both repeat winners and a wide base of new company formation.

Capital flow was uneven by month. September 2025 led the period with $651.62M, while March 2026 had the highest deal count with 13 rounds and $445.30M.

December 2025 had no disclosed deals in the screened sample. Because activity resumed immediately in January and accelerated again in March, this looks more like announcement timing than a real market pause.

How concentrated has fundraising been in the healthcare AI market?

As of July 2026, fundraising in the healthcare AI market is concentrated, but not completely dependent on one company. Across the past 12 months, the top deal represents 7.91% of all disclosed capital, while the top 10 deals represent 53.14%.

The top 3 deals account for 23.04% of disclosed dollars, and the top 5 reach 34.12%. That means the market is broad in deal count but still shaped by a small group of category leaders.

This concentration matters because the headline $3.16B total can overstate the typical company’s fundraising power. The median round is $23M, while the average is $50.16M.

How much of the healthcare AI funding signal is driven by outliers?

As of July 2026, a meaningful part of the healthcare AI funding signal is driven by outliers. Over the past 12 months, 18 deals were above $50M, and 9 deals were above $100M.

Those $50M-plus rounds represent 28.57% of all disclosed deals. That is high for a vertical software market, especially one that still has many Seed and Series A rounds.

The clearest outlier signal is the difference between average and median round size. The average deal was $50.16M, while the median was only $23M, showing how larger rounds inflate the average.

Removing rounds above $50M leaves $884.77M in disclosed capital. That is still substantial, but it also means megarounds account for about 72% of all dollars in the dataset.

Is the healthcare AI market broad with many targets, or narrow with few fundable companies?

As of July 2026, the healthcare AI market is broad in deal count but narrower in capital distribution. Across the past 12 months, 63 disclosed rounds were raised by 61 unique companies, which points to many fundable targets.

Care Workflow AI alone produced 26 deals, or 41.27% of the dataset. That shows heavy startup formation around documentation, patient access, back-office operations, care navigation, and administrative automation.

But the capital-weighted market is more selective. The top 10 deals represent 53.14% of all dollars, so the market’s strongest signal still comes from a limited set of better-validated companies.

The right interpretation is that healthcare AI has broad formation and narrow scaling. Many companies can raise, but far fewer can command late-stage or $100M-plus conviction.

Is healthcare AI mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the healthcare AI market is both an early-stage formation market and a scaling market. Over the past 12 months, Seed through Series B rounds captured $1.66B, or 52.50% of capital.

Series A was the largest stage by deal count, with 33 of 63 disclosed rounds. That equals 52.38% of the dataset, which confirms strong company formation.

Late-stage and growth rounds still matter heavily. Series C, Series D+, and Growth Equity together captured $1.48B, or 46.97% of capital, despite representing far fewer deals.

This split shows a market that is still forming new companies while already rewarding scaled winners. Investors are not just exploring healthcare AI; they are doubling down on companies with adoption, workflow depth, or platform expansion.

Which categories attract the most investor attention in healthcare AI?

As of July 2026, Care Workflow AI attracts the most investor attention in the healthcare AI market. Over the past 12 months, it produced 26 deals and $1.02B in disclosed capital.

Care Workflow AI represents 41.27% of all deals and 32.29% of all dollars. Investors are backing many companies in this layer, but the median buyer-validation signal per company is smaller than in some other categories.

Clinical AI Tools is the second-largest category by deal count, with 16 deals and $875.82M raised. It captures fewer deals than Care Workflow AI but nearly as much capital.

Life Science AI is smaller by count, with 9 deals, but still raised $667M. That makes it a major funding category even though it represents only 14.29% of disclosed rounds.

Which categories attract disproportionately large checks in the healthcare AI market?

As of July 2026, Life Science AI attracts the most disproportionately large checks in the healthcare AI market. Over the past 12 months, it held 14.29% of deals but 21.11% of capital.

That gives Life Science AI the strongest capital-share-to-deal-share ratio, at 1.48. Investors appear willing to fund larger technical-platform bets in drug discovery, molecular design, and life sciences automation.

Diagnostic AI Software also punches above its deal count. It has only 3 deals, but $171M raised, giving it a capital-to-deal-share ratio of 1.14.

Care Workflow AI has the opposite pattern. It has the most deals, but its ratio is 0.78, which suggests fragmentation across many narrower healthcare workflows rather than one dominant platform layer.

Which geographies matter most for fundraising in the healthcare AI market?

As of July 2026, North America is the clear financing center of gravity for the healthcare AI market. Over the past 12 months, North America captured 54 deals and $2.78B in disclosed capital.

That equals 85.71% of deal count and 87.88% of all dollars. The geographic skew shows that healthcare AI fundraising is still heavily indexed to U.S. provider, payer, and pharma economics.

The Middle East ranked second by capital with $173M, but that came from only 2 deals. Europe produced 5 deals and $137.80M, while Asia-Pacific produced 2 deals and $72.20M.

The average deal size was highest in the Middle East at $86.50M, followed by North America at $51.42M. But North America is the only region with both high volume and large aggregate capital.

Is the healthcare AI opportunity set broad or concentrated in one hub?

As of July 2026, the healthcare AI opportunity set is highly concentrated in one hub. Over the past 12 months, North America held 87.88% of capital and 85.71% of deals.

Europe is visible but much smaller. It accounted for 7.94% of deals and 4.36% of capital, with a median round size of $20M.

Asia-Pacific appeared in only 2 deals, but its average round size was $36.10M. That suggests selective companies can scale, even though regional deal volume remains thin.

Latin America and Africa were absent from the screened dataset. This does not mean healthcare need is absent there; it means disclosed venture funding follows monetizable healthcare IT budgets more than disease burden.

Is healthcare AI a market of small experiments or scaled financings?

As of July 2026, the healthcare AI market contains both small experiments and scaled financings, but dollars are pulled toward scaled companies. Over the past 12 months, 18 deals were $50M or larger.

The round-size distribution is still mixed. The dataset has 2 deals below $5M, 20 deals between $5M and $20M, 23 deals between $20M and $50M, and 18 deals above $50M.

This means most deals are not megarounds by count. But the market’s dollar story is still dominated by large checks, because removing $50M-plus rounds cuts total capital from $3.16B to $884.77M.

The median round size of $23M is a better guide to the typical healthcare AI company than the $50.16M average. The average is useful for market sizing, but not for understanding a normal round.

What does the typical healthcare AI round look like?

As of July 2026, the typical healthcare AI round is a mid-sized venture round rather than a giant platform financing. Over the past 12 months, the median disclosed round size was $23M.

Series A is the most common round type, with 33 deals and a median size of $22.50M. That makes Series A the best proxy for what a normal disclosed healthcare AI financing looks like.

Seed rounds are much smaller by dollars, with an average size of $11.96M and a median of $10M. They represent 17.46% of deals but only 4.16% of capital.

At the other end, Series C rounds average $129.86M, and Series D+ rounds average $200M. That shows how quickly check sizes expand once healthcare AI companies prove workflow ownership or platform potential.

Who are the investors that appear the most in healthcare AI fundraising?

As of July 2026, the clearest repeat investor in the healthcare AI market is General Catalyst. Over the past 12 months, it appeared across clinical, diagnostic, and enterprise health-system AI activity rather than one narrow workflow.

Andreessen Horowitz appeared in Ease Health and Prosper AI, both tied to healthcare workflow or operating-system themes. GV appeared through OpenEvidence and Translucent, linking clinical intelligence and health-system finance.

Insight Partners appeared in Pasito and Condor Software. Menlo Ventures, Lightspeed Venture Partners, Thrive Capital, and other investors also showed repeated exposure around agentic healthcare workflows, clinical AI, or care infrastructure.

One caveat matters. Round announcements often disclose the round size but not each investor’s individual check size, so investor repetition is safer to read as strategic participation than exact capital committed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.